Examining the Guide for Inactive Compounds (GIC)

Examining the Guide for Inactive Compounds (GIC)

The Inactive Ingredient Guide (IIG), a regulatory database published and maintained by the United States Food and Drug Administration (USFDA), is a valuable resource for pharmaceutical developers. This guide provides a comprehensive listing of excipients, also known as inactive ingredients, that have been previously approved by the FDA for use in marketed drug products.

However, it's essential to understand the key limitations and considerations when using the IIG for formulation development and ANDA submissions.

Scope and Updating

The IIG lists excipients approved in FDA-approved products but does not guarantee safety or suitability in all new formulations. It may not comprehensively cover novel excipients or new grades of existing excipients, which require separate FDA review processes.

Biological Activity of Excipients

While excipients are called "inactive," they can cause unintended biological effects such as allergies, intolerances, or severe hypersensitivity reactions. This challenges the assumption that listed excipients are universally safe and requires careful patient population consideration.

Excipient Variability and Supplier Differences

Excipient source and quality variability can affect formulation performance and product consistency. Screening multiple suppliers and qualifying them rigorously is necessary to ensure consistent raw material quality for formulations.

Potential for Excipient-API Interactions

Chemical interactions between excipients and the active pharmaceutical ingredient (API) can affect stability, leading to API degradation or impurities. For example, lactose can react via Maillard reactions with amine-containing APIs, compromising product quality.

Bioequivalence and Formulation Complexity

Changes in excipient types or amounts may alter drug bioavailability and clinical performance. Establishing bioequivalence in ANDA submissions requires careful attention to these excipient effects and often additional testing to ensure equivalence.

Lack of Robust In Vivo Data and Predictive Models

For complex, locally acting products, in vivo-in vitro correlations are limited, complicating the demonstration of bioequivalence when relying on excipient selection and characterization guided by the IIG alone.

Regulatory and Documentation Burden

The Chemistry, Manufacturing, and Controls (CMC) section of the ANDA must document excipient selection, interactions, supplier qualification, and justify any deviations from the IIG parameters. This is a detailed, intensive process driven by regulatory expectations.

Despite these limitations, using excipients at levels consistent with the IIG can support a bioequivalence waiver and minimize review queries from the FDA. If an excipient is used beyond the listed level, in a different dosage form, or via an unlisted route of administration, additional scientific or safety justification is required.

The IIG serves as a critical reference for pharmaceutical scientists, formulation developers, and regulatory affairs professionals. However, it's important to note that the IIG does not include all excipients, only those approved in existing NDAs or ANDAs. Newer excipients or those used in novel drug delivery systems may not be listed in the IIG.

During drug product development, especially for generics, formulators must justify the selection and quantity of each excipient. Inclusion in the IIG does not guarantee automatic approval for an excipient.

The IIG simplifies the regulatory review process and improves the efficiency of drug development. The guide categorizes excipients by route of administration (e.g., oral, injectable, ophthalmic, topical) and dosage form (e.g., tablet, capsule, suspension, ointment).

However, the IIG cannot be used to calculate maximum daily intake without specific methods and calculations. Sponsors must provide additional scientific or safety justification, such as toxicology reports, literature references, or published safety data, if needed.

The IIG can still serve as a useful reference for drugs submitted under 505(b)(2) or new dosage forms, but may require supplemental justification. Each listing in the IIG includes the maximum potency or quantity of an excipient as found in approved products.

It's also worth noting that the IIG cannot guarantee the safety of a drug, even if the excipients are used within the listed maximum levels.

This article was written by Moinuddin Syed, Ph.D, PMP®.

1. The Inactive Ingredient Guide (IIG) does not assure the safety or suitability of excipients in all new formulations, as it may not cover novel excipients or new grades of existing ones that need separate FDA review processes.
2. Excipients, while considered inactive, can cause unintended biological effects such as allergies, intolerances, or severe hypersensitivity reactions, challenging the assumption of universal safety.
3. Varying in source and quality, excipients can affect formulation performance and product consistency, making it necessary to screen multiple suppliers and qualify them rigorously.
4. Chemical interactions between excipients and the active pharmaceutical ingredient can impact stability and quality, necessitating careful consideration during formulation development and ANDA submissions.

Read also: